SCHEMBL25670653

SCHEMBL25670653

CNC(=O)c1cnc(NC(=O)C2CC2)nc1Nc1cccc(OC2CCOCC2)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 13/20 0.52
▸ KAT2B Q92831 1/20 0.48
▸ BAZ2B Q9UIF8 1/20 0.48
▸ JAK1 P23458 3/20 0.46
▸ ULK1 O75385 1/20 0.44
▸ PKMYT1 Q99640 1/20 0.43
▸ EGFR P00533 2/20 0.42
▸ ROS1 P08922 2/20 0.42
▸ ALK Q9UM73 2/20 0.42
▸ PTK2 Q05397 2/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ CDC7 O00311 1/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ CHEK1 O14757 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ DCLK1 O15075 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ DYRK3 O43781 1/20 0.42
▸ PRKD3 O94806 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30465841 1.00 TYK2 (0.52) TYK2KAT2BBAZ2BJAK1ULK1
SCHEMBL25669737 0.86 PKMYT1 (0.52) TYK2KAT2BBAZ2BULK1PKMYT1
SCHEMBL30465847 0.86 TYK2 (0.62) TYK2KAT2BBAZ2BJAK1JAK2
SCHEMBL25670933 0.86 TYK2 (0.62) TYK2KAT2BBAZ2BJAK1JAK2
SCHEMBL25670657 0.86 KAT2B (0.52) TYK2KAT2BBAZ2BJAK1ULK1
SCHEMBL25670916 0.81 TYK2 (0.53) TYK2JAK1JAK2CYP2C19
SCHEMBL25670928 0.80 KAT2B (0.53) TYK2KAT2BBAZ2BJAK1JAK2
SCHEMBL22313887 0.79 TYK2 (0.55) TYK2JAK1JAK2CYP2C19
SCHEMBL31017330 0.79 KAT2B (0.55) TYK2KAT2BBAZ2BJAK1PKMYT1
SCHEMBL25670612 0.78 PKMYT1 (0.43) TYK2JAK1PKMYT1EGFRPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed
WO-2023109120-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed
WO-2023108536-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TYK2 1/4885KAT2B 1329/4885BAZ2B 264/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TYK2 1/4885KAT2B 1329/4885BAZ2B 264/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 TYK2 1/4885KAT2B 1329/4885BAZ2B 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback